


AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method for the treatment of cancer comprising administration of a formulation comprising at least one compound of a pharmaceutical composition of the formulae:



X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF₃, OCF₃, COR₁, COOR₁, CONH₂, CONHR₁, and NHCOR₁;






n is an integer from one to three;

m is an integer from one to four;







R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂Ph, CH₂C₆H₄-F(p-), COCH₃, COCH₃, COOCH₂CH₃, CH₂CH₂N(CH₃)₂, and CH₂CH₂CH₂N(CH₃)₂; and

R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, and substituted heteroatom.








2. (Currently amended) The method of Claim 1, wherein method for the treatment of cancer comprises administering a formulation comprising at least one compound selected from the group consisting of










Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003










Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003

















Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003













Int'l Filing Date : March 6, 2003












Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003









Int'l Appl. No. : PCT/US03/06981







Int'l Filing Date : March 6, 2003










Int'l Filing Date : March 6, 2003










Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003



Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003














Int'l Filing Date : March 6, 2003



Int'l Appl. No. : PCT/US03/06981


Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003


B-21




B-22




B-28




B-46




B-47




B-52










B-53



















B-96













Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003



























Int'l Filing Date : March 6, 2003



Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003






















Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003







E-632




E-660




E-847




E-848




E-878




E-879




E-893




E-915




E-916




E-922




E-924




E-925




E-926




E-927




E-928




E-929




















E-930




E-931









E-13170




E-13175




E-13190




E-13191




E-13200




E-13203




E-13233











E-13234



E-13238







Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003


E-13255




E-13256




E-13259




E-13260




E-13261




E-13262




E-13263




E-13264




E-13265




E-13266




E-13268




E-13525




E-13530




E-13603




E-13604














E-13615




E-13617







3. (Original) A method for the treatment of cancer comprising administration of a formulation comprising at least one compound of a pharmaceutical composition of the formulae:



wherein:

X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF₃, OCF₃, COR₁, COOR₁, CONH₂, CONHR₁, and NHCOR₁;

n is an integer from one to three;

m is an integer from one to four;







R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂Ph, CH₂C₆H₄-F(p-), COCH₃, COCH₂CH₃, CH₂CH₂N(CH₃)₂, and CH₂CH₂CH₂N(CH₃)₂; and

R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, substituted heteroatom, aryl, and substituted aryl, wherein at least one of R₁ and R₂ is selected from aryl or substituted aryl.






Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003

4. (Currently amended) The method of Claim 3, wherein method for the treatment of cancer comprises administering a formulation comprising at least one compound selected from the group consisting of




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003


B-5




B-6




B-7




B-8




















B-9




B-10
























Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003










Int'l Appl. No. : PCT/US03/06981


Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




B-75




B-76




B-77




B-78




B-79




B-80




B-81



B-82




















B-83










Int'l Appl. No. : PCT/US03/06981







Int'l Filing Date : March 6, 2003




















Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003







B-161




B-162




B-165




B-166




B-167










B-168









B-169










Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003







B-193




B-194




B-195




B-196




B-199



B-200




B-202




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003


B-203




B-204




B-207




B-208




B-210



B-211




B-212




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003


B-213




B-214




B-215










B-216



B-217




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003


B-226




B-227




B-228




B-243



B-244




B-245




Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003


B-247




B-248




B-249




B-250




B-251



B-253




B-254




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003


B-255




B-256




B-263




B-264




B-265




B-266










B-267




B-268







B-276




B-277




B-278




B-279




B-280









B-281









B-282









Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003






Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003


E-872




E-873




E-874




E-875



E-876










E-877




Int'l Appl. No. : PCT/US03/06981


Int'l Filing Date : March 6, 2003




E-887




E-888




E-889




E-890




E-892










E-889




E-6357




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




E-13142




E-13143




E-13168




E-13169




E-13192



E-13199




E-13201




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003


E-13204




E-13205




E-13206




E-13207




E-13208



















E-13209











E-13210




















Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003







5. (Original) A method for the treatment of cancer comprising administration of a formulation comprising at least one compound of a pharmaceutical composition of the formulae:



wherein:

X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF₃, OCF₃, COR₁, COOR₁, CONH₂, CONHR₁, and NHCOR₁;

Int'l Filing Date : March 6, 2003




n is an integer from one to four;

m is an integer from one to four;


R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂Ph, CH₂C₆H₄-F(p-), COCH₃, COCH₂CH₃, CH₂CH₂N(CH₃)₂, and CH₂CH₂CH₂N(CH₃)₂; and

A and B rings independently comprise unsubstituted or substituted carbon atoms ranging from four carbon atoms to ten carbon atoms.

6. (Original) The method of Claim 5, wherein method for the treatment of cancer comprises administering a formulation comprising at least one compound selected from the group consisting of



7. (Original) A method for the treatment of cancer comprising administration of a formulation comprising at least one compound of a pharmaceutical composition of the formulae:



wherein:

X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino,

Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003

alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF_3 , OCF_3 , COR_1 , COOR_1 , CONH_2 , CONHR_1 , and NHCOR_1 ;




n is an integer from one to three;

m is an integer from one to four;


R is selected from the group consisting of H, CH_3 , C_2H_5 , C_3H_7 , C_4H_9 , CH_2Ph , $\text{CH}_2\text{C}_6\text{H}_4\text{-F(p-)}$, COCH_3 , COCH_2CH_3 , $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, and $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$; and

R_1 is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, and substituted heteroatom.

8. (Original) - The method of Claim 7, wherein method for the treatment of cancer comprises administering a formulation comprising at least one compound selected from the group consisting of



9. (Currently amended) A method for the treatment of cancer comprising administration of a formulation comprising at least one compound of a pharmaceutical composition of the formulae:



wherein:

X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, fused aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF₃, OCF₃, COOR₁, COR₂, COOR₁, COOR₂, CONH₂, CONHR₁, CONHR₂, and NHCOR₁, NHCOR₂;

n is an integer from one to three;









m is an integer from one to four;









R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂Ph, CH₂C₆H₄-F(p-), COCH₃, COCH₂CH₃, CH₂CH₂N(CH₃)₂, and CH₂CH₂CH₂N(CH₃)₂; and

R₂ is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, and substituted heteroatom.








10. (Original) The method of Claim 9, wherein method for the treatment of cancer comprises administering a formulation comprising at least one compound selected from the group consisting of

Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003






















Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003




Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003





Int'l Appl. No. : PCT/US03/06981

Int'l Filing Date : March 6, 2003



11. (Currently amended) The method ~~as in any one of the preceding claims according to Claims 1, 3, 5, 7, or 9,~~ in which the method further comprises administering at least one additional ingredient which is active in reducing at least one symptom associated with said cellular proliferation.

12. (Original) The method according to Claim 11, wherein said at least one additional ingredient is selected from the group consisting of antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.

13. (Original) The method according to Claim 11, wherein said at least one additional ingredient is selected from the group consisting of alkylating agent, antimetabolite, DNA cutter, topoisomerase I poison, topoisomerase II poison, DNA binder, and spindle poison.

14. (Currently amended) The method ~~as in any one of the preceding claims according to Claims 1, 3, 5, 7, or 9,~~ wherein said administering a formulation comprises providing to said mammal a dose of about 0.01 mg to about 100 mg per kg body weight per day.


15. (Original) The method according to Claim 14, wherein said dose is administered in divided doses at regular periodic intervals.

16. (Original) The method according to Claim 15, wherein said regular periodic intervals occur daily.

Claims 17-30 (Cancelled)


31. (New) The method of Claim 1, wherein the compound is

S-6




32. (New) The method of Claim 1, wherein the compound is

E-13619




33. (New) The method of Claim 1, wherein the compound is selected from the group consisting of


E-13603




E-13604



E-13619






E-13621












Int'l Filing Date : March 6, 2003

34. (New) A composition comprising a compound selected from the group consisting of








35. (New) A composition comprising a compound selected from the group consisting of






36. (New) A composition comprising a compound selected from the group consisting of





37. (New) A composition comprising at least one compound of a pharmaceutical composition of the formulae:



wherein:

X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF₃, OCF₃, COR₁, COOR₁, CONH₂, CONHR₁, and NHCOR₁;

n is an integer from one to four;

m is an integer from one to four;


R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂Ph, CH₂C₆H₄-F(p-), COCH₃, COCH₂CH₃, CH₂CH₂N(CH₃)₂, and CH₂CH₂CH₂N(CH₃)₂; and

A and B rings independently comprise unsubstituted or substituted carbon atoms ranging from four carbon atoms to ten carbon atoms.


Int'l Appl. No. : PCT/US03/06981
Int'l Filing Date : March 6, 2003

38. (New) The composition of Claim 37, wherein the composition comprises a compound selected from the group consisting of

E-6977



E-7305



E-15791

